Premium
Photocatalyzing CO 2 to CO for Enhanced Cancer Therapy
Author(s) -
Zheng DiWei,
Li Bin,
Li ChuXin,
Xu Lu,
Fan JinXuan,
Lei Qi,
Zhang XianZheng
Publication year - 2017
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201703822
Subject(s) - cancer cell , oxidative stress , in vivo , doxorubicin , cancer , apoptosis , cancer research , cancer therapy , materials science , cytotoxicity , pharmacology , biogenesis , mitochondrion , chemotherapy , in vitro , medicine , biochemistry , chemistry , biology , microbiology and biotechnology , gene
Continuous exposure to carbon monoxide (CO) can sensitize cancer cells to chemotherapy while protect normal cells from apoptosis. The Janus face of CO thus provides an ideal strategy for cancer therapy. Here, a photocatalytic nanomaterial (HisAgCCN) is introduced to transform endogenous CO 2 to CO for improving cancer therapy in vivo. The CO production rate of HisAgCCN reaches to 65 µmol h −1 g mat −1 , which can significantly increase the cytotoxicity of anticancer drug (doxorubicin, DOX) by 70%. Interestingly, this study finds that HisAgCCN can enhance mitochondria biogenesis and aggravate oxidative stress in cancer cells, whereas protect normal cells from chemotherapy‐induced apoptosis as well. Proteomics and metabolomics studies reveal that HisAgCCN can enhance mitochondria biogenesis and aggravate oxidative stress in cancer cells specifically. In vivo studies indicate that HisAgCCN/DOX combination therapy presents a synergetic tumor inhibition, which might provide a new direction for clinical cancer therapy.